Main users: Resident companies or institutions

A platform accelerating biopharmaceutical R&D through refined lab management and technical services. With over 30 innovation projects supported, it integrates advanced technologies and international resources to drive technological breakthroughs and foster a robust innovation ecosystem in Beijing's biopharmaceutical health sector

In order to accelerate the construction of Beijing International Science and Technology Innovation Center and strengthen the support for the landing, incubation and acceleration of original innovation achievements, Changping District Government, in collaboration with Zhongguancun Development Group and Da De Chuang Tong (Beijing) Technology Co., Ltd., jointly builds ATLATL in Zhongguancun Life Science Park.

By integrating resource elements, improving service models and shaping global brands, it will transform heavy-asset biopharmaceutical R&D investment into a light-asset innovative operation model, provide world-class laboratories and refined operation management, as well as international frontier R&D resources, provide professional solutions for enterprise development, empower projects in the process of innovative R&D, and promote the upgrading of Beijing's biopharmaceutical health industry

ATLATL promotes the upgrading of production methods by integrating advanced technologies, resources and innovative models; Link to international leading biomedical innovation resources, provide R&D environment and technical support in line with international standards for enterprises and teams, and help them achieve technological breakthroughs and innovative development;

At the same time, it is committed to building a research-oriented open innovation platform for biomedicine-through efficient models such as "assembly project" and "manufacturing enterprise" to shorten the innovation cycle and accelerate the transformation and application of scientific and technological achievements; Furthermore, it aims to build a robust, shared ecosystem for innovation governance, driving the innovative development of the biopharmaceutical industry by gathering innovative elements, originating innovation capabilities, and blending industrial resources.

ATLATL has cumulatively served more than 30 biopharmaceutical innovation projects and enterprises, with a total financing amount of nearly 2 billion yuan for enterprises, and enterprises have obtained more than 200 intellectual property rights. It has cultivated and served 15 high-tech enterprises, 3 specialised and new enterprises and 1 unicorn enterprise. It has been selected as the municipal reform and innovation practice case of " the Integrated National Demonstration Zone for Opening up the Services Sector and the China (Beijing) Pilot Free Trade Zone" construction and "capital engineering innovation practice case” and has won the Beijing science and technology enterprise incubator and leading benchmark incubator. Beijing Dart International Innovation Platform is creating an ecological cluster that gathers and originates innovation, promotes the coordinated development of various scientific and technological innovation elements and enterprises, focuses on tackling the "bottleneck" technology, grows together with innovators and entrepreneurs, manufactures innovation and reshapes innovation

In the field of biopharmaceutical health, key and emerging technology areas such as antibody drug development, gene editing, vaccine research and development, gene and cell therapy, brain science, AI drug design, biomolecular degradation, targeted RNA therapy, and other R&D innovation projects.

Da De Chuang Tong (Beijing) Technology Co., Ltd. Its founder, Zhu Pengcheng, a postdoctoral fellow from Harvard Medical School and a master's graduate from the University of Chicago Booth School of Business